Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 11
Submit an article Journal homepage
178
Views
21
CrossRef citations to date
0
Altmetric
Original Article: Research

A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry

Joanne Bareng Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
,
Iman Jilani Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
,
Mercedes Gorre Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
,
Hagop Kantarjian Department of Leukemia, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA
,
Francis J. Giles Department of Leukemia, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA
,
Alison Hannah Department of Leukemia, Kosan Biosciences, Hayward, CA, USA
&
Dr. Maher Albitar Department of Hematopathology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USACorrespondence[email protected]
 show all
Pages 2189-2195 | Received 06 Jul 2007, Accepted 31 Jul 2007, Published online: 01 Jul 2009

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Brady L. Stein, Francisco Cervantes, Francis Giles, Claire N. Harrison & Srdan Verstovsek. (2015) Novel therapies for myelofibrosis. Leukemia & Lymphoma 56:10, pages 2768-2778.
Read now
Claire E Bocchini, Moses M Kasembeli, Soung-Hun Roh & David J Tweardy. (2014) Contribution of chaperones to STAT pathway signaling. JAK-STAT 3:3.
Read now
Christian Kosan, Torsten Ginter, Thorsten Heinzel & Oliver H Krämer. (2013) STAT5 acetylation. JAK-STAT 2:4.
Read now
Ashley P. Ng. (2013) Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms. Leukemia & Lymphoma 54:5, pages 922-933.
Read now

Articles from other publishers (17)

Pei Shen, Yezhi Wang, Xiangxiang Jia, Pengfei Xu, Lian Qin, Xi Feng, Zhiyu Li & Zhixia Qiu. (2022) Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases. European Journal of Medicinal Chemistry 239, pages 114551.
Crossref
Steven De Almeida, Mathilde Regimbeau, Gaëtan Jego, Carmen Garrido, François Girodon & François Hermetet. (2020) Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. Cancers 12:9, pages 2592.
Crossref
Andrew T. Kuykendall, Nathan P. Horvat, Garima Pandey, Rami Komrokji & Gary W. Reuther. (2020) Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers 12:8, pages 2278.
Crossref
Gaëtan Jego, François Hermetet, François Girodon & Carmen Garrido. (2019) Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy. Cancers 12:1, pages 21.
Crossref
Ödül Karayazi Atici, Anna Urbanska, Sesha Gopal Gopinathan, Florence Boutillon, Vincent Goffin & Carrie S Shemanko. (2018) ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After DNA Damage. Endocrinology 159:2, pages 907-930.
Crossref
Meining Wang, Aijun Shen, Chi Zhang, Zilan Song, Jing Ai, Hongchun Liu, Liping Sun, Jian Ding, Meiyu Geng & Ao Zhang. (2016) Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions. Journal of Medicinal Chemistry 59:12, pages 5563-5586.
Crossref
Margaux Sevin, François Girodon, Carmen Garrido & Aurélie de Thonel. (2015) HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms. Mediators of Inflammation 2015, pages 1-8.
Crossref
Natali Ruchansky, Francesco Bonchi, David García-Soriano, Francesco Gullo & Nicolas Kourtellis. (2015) The Minimum Wiener Connector Problem. The Minimum Wiener Connector Problem.
B L Stein, R Swords, A Hochhaus & F Giles. (2014) Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia 28:11, pages 2139-2147.
Crossref
Olatoyosi Odenike. (2013) Beyond JAK inhibitor therapy in myelofibrosis. Hematology 2013:1, pages 545-552.
Crossref
Fabio P.S. Santos & Srdan Verstovsek. (2013) What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?. Current Opinion in Hematology 20:2, pages 123-129.
Crossref
Lindsay M. LaFave & Ross L. Levine. (2012) JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends in Pharmacological Sciences 33:11, pages 574-582.
Crossref
Oliver Weigert, Andrew A. Lane, Liat Bird, Nadja Kopp, Bjoern Chapuy, Diederik van Bodegom, Angela V. Toms, Sachie Marubayashi, Amanda L. Christie, Michael McKeown, Ronald M. Paranal, James E. Bradner, Akinori Yoda, Christoph Gaul, Eric Vangrevelinghe, Vincent Romanet, Masato Murakami, Ralph Tiedt, Nicolas Ebel, Emeline Evrot, Alain De Pover, Catherine H. Régnier, Dirk Erdmann, Francesco Hofmann, Michael J. Eck, Stephen E. Sallan, Ross L. Levine, Andrew L. Kung, Fabienne Baffert, Thomas Radimerski & David M. Weinstock. (2012) Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Journal of Experimental Medicine 209:2, pages 259-273.
Crossref
David A. Proia, Kevin P. Foley, Tim Korbut, Jim Sang, Don Smith, Richard C. Bates, Yuan Liu, Alex F. Rosenberg, Dan Zhou, Keizo Koya, James Barsoum & Ronald K. Blackman. (2011) Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling. PLoS ONE 6:4, pages e18552.
Crossref
J E Lancet, I Gojo, M Burton, M Quinn, S M Tighe, K Kersey, Z Zhong, M X Albitar, K Bhalla, A L Hannah & M R Baer. (2010) Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24:4, pages 699-705.
Crossref
Nils Schoof, Frederike von Bonin, Lorenz Trümper & Dieter Kube. (2009) HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells. Cell Communication and Signaling 7:1.
Crossref
Justin R. Pritchard, Benjamin D. Cosgrove, Michael T. Hemann, Linda G. Griffith, Jack R. Wands & Douglas A. Lauffenburger. (2009) Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Molecular Cancer Therapeutics 8:8, pages 2183-2192.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.